STAT3 and type 2 diabetes mellitus: The small molecule STAT3 inhibitor OPB-31121 was tested in a clinical trial for advanced solid tumours; however, limited efficacy and unfavourable side effects including peripheral neuropathy were reported [122], which would limit its use for CVD in the T2DM population.